| 前收盘价格 | 0.525 |
| 收盘价格 | 0.530 |
| 成交量 | 338,292 |
| 平均成交量 (3个月) | 1,505,386 |
| 市值 | 318,097,824 |
| 价格/销量 (P/S) | 54.67 |
| 股市价格/股市净资产 (P/B) | 24.45 |
| 52周波幅 | |
| 利润日期 | 21 Jul 2025 - 25 Jul 2025 |
| 营业利益率 (TTM) | -4,556.12% |
| 稀释每股收益 (EPS TTM) | -0.040 |
| 季度收入增长率 (YOY) | 116.00% |
| 总债务/股东权益 (D/E MRQ) | 2.18% |
| 流动比率 (MRQ) | 4.77 |
| 营业现金流 (OCF TTM) | -18.78 M |
| 杠杆自由现金流 (LFCF TTM) | -10.23 M |
| 资产报酬率 (ROA TTM) | -79.26% |
| 股东权益报酬率 (ROE TTM) | -524.69% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (AU) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | DIMERIX FPO [DXB] | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 2.38 |
|
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 23.75% |
| 机构持股比例 | 1.54% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合